Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore
Ullah et al.,
Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore,
International Journal of Sciences, doi:10.18483/ijSci.2417
Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment.
No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57. Baseline oxygen requirement was 13.4 liters treatment vs. 10.8 control. Potential
confounding by indication.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 100% higher, RR 2.00, p = 0.33, treatment 8 of 30 (26.7%), control 4 of 30 (13.3%).
|
risk of mechanical ventilation, 250.0% higher, RR 3.50, p = 0.15, treatment 7 of 30 (23.3%), control 2 of 30 (6.7%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ullah et al., 29 Nov 2020, retrospective, Pakistan, peer-reviewed, 8 authors.
Abstract: Efficacy of Remdesivir in Covid-19 Patients;
Multicenter Study in Lahore
Najeeb Ullah1, Khurshid A Khan2, Javeid Iqbal3,
Bilal Bin Younis4, Muhammad Asim Rana5, Mohsin Asif6,
Aijaz Zeeshan Khan Chachar7, Falak Shan8
Abstract: Introduction: This Pandemic of Covid-19 has shaken the world and devastating and unpredictable nature
of the disease and scenario becomes worse when we see limited treatment options for this disease. Objectives: The
objective of the study was to assess the efficacy of Remdesivir in patients having early phase of the disease.
Methodology: Study Settings: The study was conducted in two major tertiary care hospitals, Fatima Memorial
Hospital, Bahria international Hospital, Lahore. Sample size & Sampling Technique: A total of 60 patients were
selected for this study who were suffering from COVID 19, out of which 30 were given Remdesivir and 30 patients
were kept in control group. Participants were enrolled in the study after fulfilling inclusion and exclusion criteria. It
was Probability sampling. Study design: Non-randomized control interventional study. Data Analysis: Data was
analyzed with respect to demographics and clinical characteristics. Outcome was observed in terms of recovery and
death. Also, the oxygen requirement and respiratory rate was measured on presentation and on 14 th day of
admission. Furthermore, coexisting conditions such as diabetes, hypertension, ischemic heart disease and chronic
kidney disease were also considered regarding outcome in case group and control group. Results: Mean age of the
study participants was 53.2 with standard deviation (SD)±14.6 years, whereas average age of cases was 49.2±15.1
and control 57.1±13.1 years. Male were 60% of the patients and 40% were females, whereas both cases and control
had 57% males. The most common co existing disease was hypertension which attributed to 53% of the total sample
size followed by diabetes which was present in 47% of the study participants. 23 (38%) participants did not have
any coexisting disease. The data did not show any promises with Remdesivir therapy in patients with or without
ventilatory support in comparison with participants who did not receive Remdesivir.
Keywords: COVID 19, Pneumonia, Remdesivir
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit